Good morning :)
$
₹
Labcorp Holdings Inc.

Labcorp Holdings Inc.

LH

NYSE
Asset Logo

Labcorp Holdings Inc.

LH

NYSE
$365.733.33% (+11.81)
$
₹
$365.733.33% (+11.81)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Diagnostics & Research

Large Cap

With a market cap of $28.9B the stock is ranked 484

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

29.14
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.26
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$12.2
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.57
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

6.88%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

0.8%

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 17 analysts reports

Buy
12 analysts
Hold
5 analysts
Sell
0 analyst

Price Upside

+8%

Earnings Growth

+12.42%

Rev. Growth

+6.2%

See Detailed Forecast

Company Profile

Company Profile

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
CVS Health Corp
CVS
CVS Health Corp
P/E Ratio
23.29
23.29
1Y Return
12.83%
12.83%
Buy Reco %
92.59
92.59
The Cigna Group
CI
The Cigna Group
P/E Ratio
12.20
12.20
1Y Return
14.14%
14.14%
Buy Reco %
70.83
70.83
Quest Diagnostics Incorporated
DGX
Quest Diagnostics Incorporated
P/E Ratio
24.98
24.98
1Y Return
40.24%
40.24%
Buy Reco %
52.94
52.94
Guardant Health Inc
GH
Guardant Health Inc
P/E Ratio
—
—
1Y Return
76.91%
76.91%
Buy Reco %
96.15
96.15
BrightSpring Health Services, Inc. Common Stock
BTSG
BrightSpring Health Services, Inc. Common Stock
P/E Ratio
46.99
46.99
1Y Return
97.85%
97.85%
Buy Reco %
100.00
100.00
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 8.00% growth, versus a trailing 3-year CAGR of 20.06%.

2026
Current$353.92Baseline
Analyst Target - 1 year
Target$382.25+8%

All values in $

202220232024202520262027$236.70$297.96$359.22Target+8%
2026
Current$353.92Baseline
Analyst Target - 1 year
Target$382.25+8%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 6.20% growth, versus a trailing 3-year CAGR of 5.55%.

2025
Current$13.95Baseline
Forecast for Dec 2026
High$14.86+6.56%
Average$14.81+6.2%
Low$14.72+5.56%

All values in $ Billion

20212022202320242025202613.1311.8612.1613.0013.95Low+5.56%Average+6.2%High+6.56%
2025
Current$13.95Baseline
Forecast for Dec 2026
High$14.86+6.56%
Average$14.81+6.2%
Low$14.72+5.56%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Higher earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 12.42% growth, versus a trailing 3-year CAGR of -6.15%.

2025
Current$16.44Baseline
Forecast for Dec 2026
High$18.62+13.25%
Average$18.48+12.42%
Low$18.24+10.95%

All values in $

20212022202320242025202628.5119.8913.9214.5716.44Low+10.95%Average+12.42%High+13.25%
2025
Current$16.44Baseline
Forecast for Dec 2026
High$18.62+13.25%
Average$18.48+12.42%
Low$18.24+10.95%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

3.5
0.1
3.5
0.2
3.7
0.2
3.8
0.2
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue3.223.283.323.343.523.563.513.533.733.81
Net Income0.200.160.140.210.230.260.160.270.290.26
Net Profit Margin6.37%5.15%4.30%6.36%6.74%7.32%4.68%7.85%8.00%6.89%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDiagnostics & Research

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Labcorp Holdings Inc. 29.143.261.57
CVS Health Corp23.291.440.21
The Cigna Group12.201.840.81
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare LH with any stock or ETF
Compare LH with any stock or ETF
Comparing from
LH
CVS
CI
Loading...

Frequently asked questions

  1. Labcorp Holdings Inc. (LH) share price today is $365.73 as of November 5, 2026 at 1:23 AM IST. The stock touched a day high of $367.35 and a day low of $356.69.

  2. Labcorp Holdings Inc. stock trades on NYSE under the ticker symbol LH.

  3. Labcorp Holdings Inc.'s market capitalization is $28.87B as of November 5, 2026 at 1:23 AM IST.

  4. Labcorp Holdings Inc.'s price-to-earnings (P/E) ratio is 29.14 as of November 4, 2026.

  5. Labcorp Holdings Inc.'s price-to-book (P/B) ratio is 3.26 as of November 4, 2026.

  6. Yes, Labcorp Holdings Inc. pays a dividend, with a current dividend yield of 0.8%.

  7. Yes, You can buy Labcorp Holdings Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Labcorp Holdings Inc. shares in three steps: 1. Search Labcorp Holdings Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Labcorp Holdings Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Labcorp Holdings Inc. (LH) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0273 shares at the current price of $365.73.

Loading...